VINORELBINE ALVOGEN SOFT CAPSULES 30MG

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

即購入

製品の特徴 製品の特徴 (SPC)
28-04-2021

有効成分:

Vinorelbine Tartrate eqv. Vinorelbine

から入手可能:

LOTUS INTERNATIONAL PTE. LTD.

ATCコード:

L01CA04

医薬品形態:

CAPSULE, LIQUID FILLED

構図:

Vinorelbine Tartrate eqv. Vinorelbine 30.00 mg

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

Lotus Pharmaceutical Co., Ltd. Nantou Plant

認証ステータス:

ACTIVE

承認日:

2021-04-28

製品の特徴

                                1
NAME OF THE MEDICINAL PRODUCT
Vinorelbine Alvogen 20 mg soft capsule
Vinorelbine Alvogen 30 mg soft capsule
Vinorelbine Alvogen 80 mg soft capsule
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each soft capsule contains vinorelbine tartrate 27.70 mg equivalent to
20 mg vinorelbine.
Each soft capsule contains vinorelbine tartrate 41.55 mg equivalent to
30 mg vinorelbine.
Each soft capsule contains vinorelbine tartrate 110.80 mg equivalent
to 80 mg vinorelbine.
Excipient with known effect
Each soft capsule containing 20 mg vinorelbine contains 38.439 mg
sorbitol.
Each soft capsule containing 30 mg vinorelbine contains 59.850 mg
sorbitol.
Each soft capsule containing 80 mg vinorelbine contains 99.905 mg
sorbitol.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Soft capsule
Vinorelbine Alvogen 20 mg soft capsule: An oval-shaped light brown
soft capsule, with the size of
11x7 mm filled with a transparent, colourless to slightly yellow
liquid.
Vinorelbine Alvogen 30 mg soft capsule: An oblong-shaped pink soft
capsule, with the size of
18x6 mm filled with a transparent, colourless to slightly yellow
liquid.
Vinorelbine Alvogen 80 mg soft capsule: An oblong-shaped pale yellow
soft capsule, with the size of
21x8 mm filled with a transparent, colourless to slightly yellow
liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Vinorelbine is indicated in adults for:
•
Non-small cell lung cancer
•
Advanced Breast Cancer.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
•
AS A SINGLE AGENT:
Adult patients
The recommended regimen is:
_First three administrations _
60 mg/m² of body surface area, administered once weekly
_Subsequent administrations _
After the third administration, it is recommended to increase the dose
of vinorelbine to 80 mg/m² once
weekly except in those patients for whom the neutrophil count dropped
once <500/mm
3
or more than
once between 500 and 1,000/mm
3
during the first three administrations at 60 mg/m².
2
Neutrophil count during the first 3
administrations of 60
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索